Exelixis, Inc. (NASDAQ:EXEL) Director Alan M. Garber sold 11,250 shares of the firm’s stock in a transaction on Tuesday, January 8th. The stock was sold at an average price of $23.00, for a total value of $258,750.00. Following the completion of the transaction, the director now directly owns 72,579 shares in the company, valued at $1,669,317. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
NASDAQ:EXEL opened at $24.07 on Friday. The company has a current ratio of 8.66, a quick ratio of 8.54 and a debt-to-equity ratio of 0.01. The stock has a market cap of $7.08 billion, a price-to-earnings ratio of 20.06, a price-to-earnings-growth ratio of 1.46 and a beta of 2.09. Exelixis, Inc. has a 52 week low of $13.42 and a 52 week high of $31.79.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Thursday, November 1st. The biotechnology company reported $0.41 EPS for the quarter, beating the Zacks’ consensus estimate of $0.19 by $0.22. The business had revenue of $225.40 million for the quarter, compared to analysts’ expectations of $174.14 million. Exelixis had a return on equity of 55.71% and a net margin of 49.53%. The business’s quarterly revenue was up 47.8% on a year-over-year basis. During the same period last year, the firm earned $0.26 earnings per share. As a group, analysts predict that Exelixis, Inc. will post 1.3 earnings per share for the current fiscal year.
EXEL has been the topic of a number of recent research reports. Guggenheim initiated coverage on Exelixis in a report on Monday, September 17th. They issued a “buy” rating on the stock. Goldman Sachs Group initiated coverage on Exelixis in a report on Monday, September 17th. They issued a “neutral” rating and a $22.00 target price on the stock. BidaskClub cut Exelixis from a “sell” rating to a “strong sell” rating in a report on Friday, September 14th. Oppenheimer set a $40.00 price target on Exelixis and gave the company a “buy” rating in a report on Thursday, November 15th. Finally, Piper Jaffray Companies decreased their price target on Exelixis from $29.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday, November 5th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $28.38.
A number of large investors have recently bought and sold shares of EXEL. Retirement Systems of Alabama grew its position in shares of Exelixis by 0.6% during the fourth quarter. Retirement Systems of Alabama now owns 387,465 shares of the biotechnology company’s stock valued at $7,621,000 after purchasing an additional 2,485 shares in the last quarter. Teachers Advisors LLC grew its position in shares of Exelixis by 0.7% during the third quarter. Teachers Advisors LLC now owns 347,144 shares of the biotechnology company’s stock valued at $6,151,000 after purchasing an additional 2,577 shares in the last quarter. Vanguard Group Inc grew its position in shares of Exelixis by 3.2% during the third quarter. Vanguard Group Inc now owns 26,527,089 shares of the biotechnology company’s stock valued at $470,060,000 after purchasing an additional 834,478 shares in the last quarter. Marshall Wace LLP grew its position in shares of Exelixis by 109.1% during the third quarter. Marshall Wace LLP now owns 1,627,313 shares of the biotechnology company’s stock valued at $28,836,000 after purchasing an additional 849,096 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Exelixis by 3.2% during the third quarter. Vanguard Group Inc. now owns 26,527,089 shares of the biotechnology company’s stock valued at $470,060,000 after purchasing an additional 834,478 shares in the last quarter. 77.22% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Alan M. Garber Sells 11,250 Shares of Exelixis, Inc. (EXEL) Stock” was originally posted by Fairfield Current and is the property of of Fairfield Current. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.fairfieldcurrent.com/news/2019/01/11/alan-m-garber-sells-11250-shares-of-exelixis-inc-exel-stock.html.
Exelixis Company Profile
Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Featured Story: Market Capitalization
Receive News & Ratings for Exelixis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Exelixis and related companies with MarketBeat.com’s FREE daily email newsletter.